New trial shows top-selling Lundbeck drug not beating placebo for borderline
A phase II trial of one of Lundbeck's best-selling drugs for borderline personality disorder has not shown the hoped-for result, as the drug doesn't outperform the placebo treatment in the study's focal point.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY L. N. BARNES
Lundbeck suffers a setback in its attempts to promote the use of Rexulti, which is already among the company's best-selling products, reads the pharmaceutical company's Q2 report released Wednesday morning.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
